RFP for Pre-clinical and Translational Research in Multiple Myeloma
Pfizer has issued an RFP for its Pre-clinical and Translational Research in Multiple Myeloma grant program.
Grants of up to $150,000 will be awarded in support of pre-clinical and translational research in multiple myeloma. Only pre-clinical projects with a focus on these areas of interest will be considered: correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy; understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment; mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion); correlation between soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity); impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations); mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity; exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) with a focus on drugs that are not currently SOC in myeloma; immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity; and comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab.
Studies can be in-vitro or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates). A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies.
The applicant (principal investigator) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy. Applicant must be affiliated with a host institution, and only organizations are eligible to receive grants, not individuals or medical practice groups.
For complete program guidelines and application instructions, see the Pfizer website.
Submissions to this sponsor/donor are managed by the Office of Corporate and Foundation Relations. Please contact your unit-assigned ASUF Director of Development or Research Advancement Specialist at your earliest convenience to ensure ASU's strategic coordination and management of funding applications.